Product Name |
SARS-CoV-2 Spike Glycoprotein RBD mRNA, United Kingdom Variant |
Description |
This modified mRNA encodes the United Kingdom variant of the spike glycoprotein receptor binding domain (RBD, Arg319-Phe541) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). This RBD mutant has N501Y mutation in the S glycoprotein RBD as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416).
|
Features |
- 5' Cap: Capped with ARCA (Anti Reverse Cap Analog, m7(3'-O-methyl)-G(5')ppp(5')G, Cap 0) or CleanCap AG (m7G(5')ppp(5')(2'OMeA)pG, Cap 1)
- 5’-UTR: derived from human alpha-globin RNA with an optimized Kozak sequence
- Codon Optimization: Human
- Mutation: N501Y
- Nucleotide Modifications: mRNA modified with both Pseudo-UTP and 5mCTP
- 3’-UTR: comprises two sequence elements derived from the amino-terminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA to confer RNA stability and high total protein expression.
- PolyA: 180 nt
|
Sequence |
Available upon request.
|
Application |
Animal Vaccine Research (Not for human use) |
Concentration |
~1 μg/μl |
Transfection Protocol |
Lipofectamine™ MessengerMAX™ Transfection Reagent Protocol |
QC |
Agarose gel electrophoresis |
Shipping |
Dry ice |
Storage |
-80 oC |